Document is current
Any future updates will be listed below
-
Authors
Klug, Sebastian https://orcid.org/0000-0001-8714-6608
Godbersen, Godber M. https://orcid.org/0000-0002-9739-0724
Rischka, Lucas https://orcid.org/0000-0002-6766-857X
Wadsak, Wolfgang https://orcid.org/0000-0003-4479-8053
Pichler, Verena https://orcid.org/0000-0003-4544-2438
Klöbl, Manfred
Hacker, Marcus https://orcid.org/0000-0002-4222-4083
Lanzenberger, Rupert https://orcid.org/0000-0003-4641-9539
Hahn, Andreas https://orcid.org/0000-0001-9727-7580
-
Funding
Funding for this research was provided by:
Medizinische Universität Wien (MDPhD Excellence Program)
Österreichischen Akademie der Wissenschaften (DOC Fellowship, DOC Fellowship)
Austrian Science Fund (KLI 610)
- License Information
-
More Information
Article History
Received: 26 November 2021
Accepted: 12 April 2022
First Online: 9 May 2022
Competing interests
: The authors declare the following competing interests: R.L. received travel grants and/or conference speaker honoraria within the last 3 years from Bruker BioSpin MR and Heel, and has served as a consultant for Ono Pharmaceutical. He received investigator-initiated research funding from Siemens Healthcare regarding clinical research using PET/MRI. He is a shareholder of the start-up company BM Health GmbH since 2019. M.H. received consulting fees and/or honoraria from Bayer Healthcare BMS, Eli Lilly, EZAG, GE Healthcare, Ipsen, ITM, Janssen, Roche, and Siemens Healthineers. W.W. declares to having received speaker honoraria from the GE Healthcare and research grants from Ipsen Pharma, Eckert-Ziegler AG, Scintomics, and ITG; and working as a part time employee of CBmed Ltd. (Center for Biomarker Research in Medicine, Graz, Austria). The remaining authors declare no competing interests.
